美国 · SEC FORM 4
Kyverna Therapeutics, Inc.
KYTX · Nasdaq · CIK 0001994702 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
5 同一窗口内观察到的 Form 4 交易行
0 sales · 5 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-18 · SEIDENBERG BETH C.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 9,618,412
- 上期报告
- 8,766,334
- 日均成交量
- 1,086,231
- 回补天数
- 8.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | Westlake BioPartners Fund I, L.P.; Westlake BioPartners GP I, LLC; Westlake BioPartners Opportunity Fund I, L.P.; Westlake BioPartners Opportunity GP I, LLC | 买入 (P) | Common Stock | 133,333 | USD 7.50 | USD 999,998 | SEC 申报 ↗ |
| 2025-12-18 | SEIDENBERG BETH C | 买入 (P) | Common Stock | 133,333 | USD 7.50 | USD 999,998 | SEC 申报 ↗ |
| 2024-02-12 | Vida Ventures GP III, L.L.C.; Vida Ventures III, L.P.; Vida Ventures III-A, L.P.; Vida Ventures, LLC | 买入 (P) | Common Stock | 253,136 | USD 22.00 | USD 5,568,992 | SEC 申报 ↗ |
| 2024-02-12 | Bain Capital Life Sciences Fund III, L.P.; Bain Capital Life Sciences III General Partner, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Opportunities III GP, LLC; Bain Capital Life Sciences Opportunities III, LP | 买入 (P) | Common Stock | 450,000 | USD 22.00 | USD 9,900,000 | SEC 申报 ↗ |
| 2024-02-12 | GILEAD SCIENCES, INC. | 买入 (P) | Common Stock | 910,000 | USD 22.00 | USD 20,020,000 | SEC 申报 ↗ |
| 2024-02-12 | Northpond Ventures III GP, LLC; Northpond Ventures III, LP; Rubin Michael P. | 买入 (P) | Common Stock | 450,000 | USD 22.00 | USD 9,900,000 | SEC 申报 ↗ |
Form 4 申报证据
16 transaction lines in the latest 365-day window; 41 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | Shaw Christi | 代扣税 (F) | Common Stock | 4,194 | USD 8.59 | USD 36,026 | SEC 申报 ↗ |
| 2026-05-27 | SEIDENBERG BETH C | 奖励／授予 (A) | Common Stock | 5,093 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Cohen Fred E | 奖励／授予 (A) | Common Stock | 5,093 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (15 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | Shaw Christi | 代扣税 (F) | Common Stock | 4,194 | USD 8.59 | USD 36,026 | SEC 申报 ↗ |
| 2026-05-27 | SEIDENBERG BETH C | 奖励／授予 (A) | Common Stock | 5,093 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Cohen Fred E | 奖励／授予 (A) | Common Stock | 5,093 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | CLARK IAN T | 奖励／授予 (A) | Common Stock | 5,093 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Aktar Mert | 奖励／授予 (A) | Common Stock | 5,093 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-13 | GRASSO MARC | 奖励／授予 (A) | Common Stock | 10,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-13 | GEHCHAN NAJI | 奖励／授予 (A) | Common Stock | 18,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-13 | Biddle Warner Weston | 奖励／授予 (A) | Common Stock | 58,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-24 | Miller Andrew Craig | 奖励／授予 (A) | Common Stock | 11,006 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-24 | Emany Sravan Kumar | 奖励／授予 (A) | Common Stock | 11,006 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | Shaw Christi | 奖励／授予 (A) | Common Stock | 54,301 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-18 | Westlake BioPartners Fund I, L.P.; Westlake BioPartners GP I, LLC; Westlake BioPartners Opportunity Fund I, L.P.; Westlake BioPartners Opportunity GP I, LLC | 买入 (P) | Common Stock | 133,333 | USD 7.50 | USD 999,998 | SEC 申报 ↗ |
| 2025-12-18 | SEIDENBERG BETH C | 买入 (P) | Common Stock | 133,333 | USD 7.50 | USD 999,998 | SEC 申报 ↗ |
| 2025-12-15 | Walker Karen Marie | 卖出 (S) | Common Stock | 23,998 | USD 12.20 | USD 292,776 | SEC 申报 ↗ |
| 2025-12-15 | Walker Karen Marie | 期权行权／转换 (M) | Common Stock | 23,998 | USD 4.83 | USD 115,910 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | KYTX |
| CIK | 0001994702 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 41 transaction lines from 2024-02-12 to 2026-05-27 7 P purchase lines · 1 S sale lines · 33 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.